OS Therapies Incorporated (OSTX)

OS Therapies Statistics

Total Valuation

OS Therapies has a market cap or net worth of $53.53 million. The enterprise value is $51.65 million.

Market Cap	53.53M
Enterprise Value	51.65M

Important Dates

The next estimated earnings date is Monday, March 30, 2026, after market close.

Earnings Date	Mar 30, 2026
Ex-Dividend Date	n/a

Share Statistics

OS Therapies has 35.21 million shares outstanding. The number of shares has increased by 481.00% in one year.

Current Share Class	35.21M
Shares Outstanding	35.21M
Shares Change (YoY)	+481.00%
Shares Change (QoQ)	+27.24%
Owned by Insiders (%)	15.71%
Owned by Institutions (%)	5.08%
Float	26.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	13.90
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.56

Current Ratio	0.56
Quick Ratio	0.45
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2,605.11

Financial Efficiency

Return on equity (ROE) is -914.04% and return on invested capital (ROIC) is -615.01%.

Return on Equity (ROE)	-914.04%
Return on Assets (ROA)	-225.11%
Return on Invested Capital (ROIC)	-615.01%
Return on Capital Employed (ROCE)	-409.41%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-$4.05M
Employee Count	5
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -5.59% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-5.59%
50-Day Moving Average	1.41
200-Day Moving Average	1.76
Relative Strength Index (RSI)	55.50
Average Volume (20 Days)	452,364

Short Selling Information

The latest short interest is 1.55 million, so 4.41% of the outstanding shares have been sold short.

Short Interest	1.55M
Short Previous Month	965,726
Short % of Shares Out	4.41%
Short % of Float	5.77%
Short Ratio (days to cover)	3.34

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-19.68M
Pretax Income	-18.28M
Net Income	-20.26M
EBITDA	-19.44M
EBIT	-19.68M
Earnings Per Share (EPS)	-$0.78

Balance Sheet

The company has $1.88 million in cash and n/a in debt, with a net cash position of $1.88 million or $0.05 per share.

Cash & Cash Equivalents	1.88M
Total Debt	n/a
Net Cash	1.88M
Net Cash Per Share	$0.05
Equity (Book Value)	4.71M
Book Value Per Share	0.11
Working Capital	-1.82M

Cash Flow

Operating Cash Flow	-12.88M
Capital Expenditures	n/a
Free Cash Flow	-12.88M
FCF Per Share	-$0.37

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

OS Therapies does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-481.00%
Shareholder Yield	-481.00%
Earnings Yield	-37.84%
FCF Yield	-24.07%

Analyst Forecast

The average price target for OS Therapies is $18.50, which is 1,117.11% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$18.50
Price Target Difference	1,117.11%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1